Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

This study is an addition to the ongoing pediatric studies (CHIME 1 and CHIME 2) to assess
the efficacy and safety of SPN-810 in the improvement of impulsive aggression (IA) behaviors
in adolescents with ADHD.

SPN-810 will be administered in patients diagnosed with ADHD and associated feature of IA,
who are currently being treated with an FDA-approved standard ADHD treatment and with
persistent IA behaviors. The frequency of impulsive aggressive behaviors will be assessed as
a primary outcome.

Inclusion Criteria:

- Otherwise, healthy non-smoking, male and females adolescents (12-17 years of age at
the time of screening) with a primary diagnosis of ADHD and currently taking an
optimized FDA-approved ADHD medication.

- IA will be confirmed at screening using R-MOAS scale and Vitiello Aggression
Questionnaire.

Exclusion Criteria:

- History or current diagnosis of epilepsy, major depressive disorder, bipolar disorder,
schizophrenia and other psychotic disorders, personality disorder, Tourette's syndrome
or dissociative disorder, autism spectrum disorder, pervasive developmental disorder,
obsessive compulsive disorder, post-traumatic stress disorder, or intermittent
explosive disorder.

- Currently meeting DSM-5 criteria for pervasive developmental disorder, obsessive
compulsive disorder, post-traumatic stress disorder or intermittent explosive
disorder.

- Known or suspected intelligence quotient (IQ) <70, active suicidal plan/intent or
active suicidal thought, criminal arrest, alcohol or drug use or pregnancy.